Monte Rosa Therapeutics Accounts Payable

As of the most recent data (June 2026), GLUE shows a accounts payable of $7.2M. That compares with $5.6M in the prior-year period — up 28.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GLUE's accounts payable is now $7.2M (was $5.6M) — a 28.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Monte Rosa Therapeutics is outperforming or lagging.

Tracking GLUE's accounts payable over time shows whether Monte Rosa Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $7.2M That compares with $5.6M in the prior-year period — up 28.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Monte Rosa Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $7.2M) with ownership activity and broader fundamentals.

Monte Rosa Therapeutics's accounts payable is $7.2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.